Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares CANF
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $7.50 (+396.7% upside)
Key Stats
- Today's Range
- $1.47 – $1.61
- 50-Day Range
- $1.42 – $2.39
- 52-Week Range
- $1.42 – $12.30
- Volume
- 37K shs
- Average Volume
- 59K shs
- Market Cap
- $4.64 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.49%
- Days to Cover
- 1.00
About Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Related Stocks
Compare head-to-head: CANF vs AAPL·CANF vs MSFT·CANF vs NVDA·CANF vs GOOGL
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
